Sat, January 25, 2025
Fri, January 24, 2025
Thu, January 23, 2025
Wed, January 22, 2025
Tue, January 21, 2025
Mon, January 20, 2025
[ Mon, Jan 20th ] - WOFL
10 new museums opening in 2025
Sun, January 19, 2025
Sat, January 18, 2025
Fri, January 17, 2025
Thu, January 16, 2025
Wed, January 15, 2025

AstraZeneca secures first BTK approval in first-line mantle cell lymphoma


//science-technology.news-articles.net/content/2 .. approval-in-first-line-mantle-cell-lymphoma.html
Published in Science and Technology on Monday, January 20th 2025 at 16:42 GMT by MSN   Print publication without navigation

  • The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

AstraZeneca has received its first approval for a BTK inhibitor, Calquence (acalabrutinib), in combination with bendamustine and rituximab for the first-line treatment of mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma. This approval by the European Commission marks a significant advancement as it offers a new treatment option for MCL patients who are not eligible for stem cell transplant. The approval was supported by data from the ECHO trial, which demonstrated that the combination therapy significantly improved progression-free survival compared to standard treatments. This development not only expands AstraZeneca's oncology portfolio but also provides a less toxic alternative to traditional chemotherapy, potentially improving patient outcomes and quality of life.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biochemistry/astrazeneca-secures-first-btk-approval-in-first-line-mantle-cell-lymphoma/ar-AA1xxTxt ]

Publication Contributing Sources